Anlotinib

DB11885InvestigationalSmall molecule

Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.

Mechanism: Pharmacologically active on Vascular endothelial growth factor receptor 3, Platelet-derived growth factor receptor beta, and Vascular endothelial growth factor receptor 2
Curator reviewed
Formula / weight: C₂₃H₂₂FN₃O₃ · 407.445 g/mol (avg)
Also known as: Anrotenib · Arotinib · Catequentinib
Code names: AL-3818

Resolves to

Compound

Structure

InChIKeyKSMZEXLVHXZPEF-UHFFFAOYSA-NSMILESCOC1=CC2=C(OC3=CC=C4NC(C)=CC4=C3F)C=CN=C2C=C1OCC1(N)CC1

Targets

What you can answer from here — as of July 17, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

418Clinical trialsPhase, status and sponsor resolved per trial

13+ReferencesStructured and connected to the statements they support

Which drugs share a target with Anlotinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.